611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Basic InformationLatest News
Insurance Often Covers Ivermectin for COVID, Even Though Drug Doesn't WorkMedicaid Rules May Affect Americans' Cancer SurvivalMedicare Proposes to Only Cover Alzheimer's Drug Aduhelm for Use in Clinical TrialsMedicare May Rethink Premium Hike for Pricey Alzheimer’s DrugAduhelm: Will Medicare Cover the Controversial Alzheimer's Drug?Many Seniors on Medicare Falling Into Medical DebtPricey Alzheimer's Drug Drives Spike in Medicare B Premium: OfficialsWorkers' Share of Annual Premium for Employer Health Plans Nears $6,000Millions Who Joined Medicaid During Health Emergency Could Soon Lose CoverageTurning 65 Brings Big Health Care Cost Savings, Study FindsObamacare's Medicaid Expansion Helped Americans' Blood PressureLittle Change in Number of Uninsured in  Pandemic's First YearHow Did New 'Surprise Medical Bill' Laws Affect Your State?Americans Have High Trust in Health Care Providers: PollLowering Medicare Age Could Help Close Racial Gaps in Health Care: StudyPatients of Color Less Likely to Get Specialist Care Than White PatientsMany Patients Billed for Preventive Care That Should Be Free: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugCancer Survivors Fared Better Financially After ObamacareAthletes Face Twice the Odds for A-FibU.S. Supreme Court Strikes Down Challenge to Affordable Care ActWhen Cardiac Deaths Rose During Pandemic, Minorities Suffered MostAs Medicaid Access Expands, So Does Cancer SurvivalFor the Poor, Even a Small Medical Bill Can Trigger Coverage LossState of Mind Matters for Survival After Heart AttackBuying Your Own Health Insurance Just Got Way Less ExpensiveChoice of Brand-Name Drug Over Generics Costs Medicare Nearly $2 Billion Annually
Questions and AnswersLinksBook Reviews
Related Topics

Health Insurance
Health Policy & Advocacy

Medicare May Rethink Premium Hike for Pricey Alzheimer’s Drug

HealthDay News
by Robin Foster and Robert Preidt
Updated: Jan 10th 2022

new article illustration

MONDAY, Jan. 10, 2022 (HealthDay News) -- Medicare has been told to reassess a significant premium increase it had announced that largely stemmed from the expensive new Alzheimer's drug Aduhelm.

U.S. Health and Human Services Secretary Xavier Becerra's directive, which was announced on Monday, comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.

“With the 50% price drop of Aduhelm on Jan. 1, there is a compelling basis ... to reexamine the previous recommendation,” Becerra said in a statement.

The standard Part B premium is scheduled to rise by about $22 this year, up from $148.50 in 2021. It would be one of the biggest annual increases ever. About $11 of the increase was attributed to the potential costs of having to cover Aduhelm at its original $56,000 price tag.

There will be no immediate change to premiums for the more than 50 million Medicare recipients who pay the $170.10 monthly Part B premium for outpatient care, but Becerra's order to the U.S. Centers for Medicare and Medicaid Services (CMS) could lead to a reduction later in the year, the Associated Press reported.

In June, the U.S. Food and Drug Administration's approval of Aduhelm (aducanumab) ignited a backlash from the medical community because clinical trials showed the drug didn't trigger any clear improvement in brain function. It also came with safety concerns.

But groups like the Alzheimer's Association argued that Aduhelm's success could pave the way for even better treatments for the memory-robbing disease.

"It's always been a progression from first treatments that weren't by any means all that we hoped for, but were an important first step leading to progressive advances, treatment by treatment, as we learned more and we had further research and development," Robert Egge, chief policy officer for the Alzheimer's Association, told HealthDay News last week. "That's the path we see before us for Alzheimer's disease."

Still, critics of the drug say CMS has essentially been forced to rectify a grave error made by the FDA when it approved Aduhelm based on shaky evidence.

"The drug, given the available evidence, provides false hope to Alzheimer's disease patients and their families," Dr. Michael Carome, director of Public Citizen's Health Research Group, said to HealthDay News. "The right decision for CMS is to not cover the drug until there's sufficient evidence that the drug works."

When it announced the lower price for Aduhelm, Biogen acknowledged that the high cost had discouraged use of the medication by Alzheimer's patients.

"Too many patients are not being offered the choice of Aduhelm due to financial considerations and are thus progressing beyond the point of benefitting from the first treatment to address an underlying pathology of Alzheimer’s disease," Biogen CEO Michel Vounatsos said in a statement at the time. "We recognize that this challenge must be addressed in a way that is perceived to be sustainable for the U.S. health care system."

Currently, Medicare is covering Aduhelm on a case-by-case basis but is expected to announce an initial coverage decision later this week, the AP reported. However, finalizing that decision could take months.

More information

Visit the Alzheimer's Association for more on Aduhelm.

SOURCE: Associated Press